Vertex Pharmaceuticals Inc has gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.
Vertex’s pill, called Journavx, received US Food and Drug Administration clearance to treat moderate to severe acute pain, a statement said on Thursday. The wholesale acquisition cost for the twice-daily medicine is set at US$15.50 per 50 milligram tablet, Vertex said.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures. More than half a million US deaths were linked to overdoses of the addictive drugs from 1999 to 2019, official figures show, with more than 70,000 in the year through June last year alone.
Photo:AP
While some fatalities involved use of illicit drugs, many people begin taking them after they lost access to prescribed opioids, leading doctors and health officials to look for other options.
Vertex’s drug has been hailed as a scientific breakthrough, because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can lead patients to ramp up doses to dangerous levels. It is a key to Vertex’s strategy of diversifying beyond its core business centered on cystic fibrosis treatments.
While some analysts predict the painkiller would become a multibillion-dollar product for a company needing a growth driver, questions remain about its price and commercial potential. Health insurers and hospitals might continue steering patients to opioids, which — while dangerous — are cheap and effective.
Vertex has been pressing Congress to create policies that would help its product succeed. For example, the No Pain Act, which provides extra Medicare reimbursement to hospitals that prescribe alternatives to opioids, went into effect this year.
The company plans to focus on selling its drug to the about 2,000 US hospitals that see about two-thirds of patients in acute pain, chief operating officer Stuart Arbuckle said.
Boston-based Vertex, the maker of cystic fibrosis treatments like the blockbuster Trikafta, has worked for more than two decades to develop a nonaddictive pain drug. Journavx, also called suzetrigine, blocks a structure in the nerve cells that send pain signals to the brain.
In late-stage studies of patients with acute pain after surgery, Vertex’s drug worked better than a placebo, but failed to reduce pain faster than a combination of acetaminophen, better known as Tylenol, and an opioid. That could present a challenge for Vertex, as new drugs typically must outperform what is already on the market to gain traction.
Vertex is studying the same pill to treat chronic pain lasting at least three months, which affects about 50 million Americans. The company encountered a setback in December when a mid-stage trial showed the drug failed to work better than a placebo in lower back pain, causing the shares to plunge.
A new online voting system aimed at boosting turnout among the Philippines’ millions of overseas workers ahead of Monday’s mid-term elections has been marked by confusion and fears of disenfranchisement. Thousands of overseas Filipino workers have already cast their ballots in the race dominated by a bitter feud between President Ferdinand Marcos Jr and his impeached vice president, Sara Duterte. While official turnout figures are not yet publicly available, data from the Philippine Commission on Elections (COMELEC) showed that at least 134,000 of the 1.22 million registered overseas voters have signed up for the new online system, which opened on April 13. However,
EUROPEAN FUTURE? Albanian Prime Minister Edi Rama says only he could secure EU membership, but challenges remain in dealing with corruption and a brain drain Albanian Prime Minister Edi Rama seeks to win an unprecedented fourth term, pledging to finally take the country into the EU and turn it into a hot tourist destination with some help from the Trump family. The artist-turned-politician has been pitching Albania as a trendy coastal destination, which has helped to drive up tourism arrivals to a record 11 million last year. US President Donald Trump’s son-in-law, Jared Kushner, also joined in the rush, pledging to invest US$1.4 billion to turn a largely deserted island into a luxurious getaway. Rama is expected to win another term after yesterday’s vote. The vote would
ALLIES: Calling Putin his ‘old friend,’ Xi said Beijing stood alongside Russia ‘in the face of the international counter-current of unilateralism and hegemonic bullying’ Chinese President Xi Jinping (習近平) yesterday was in Moscow for a state visit ahead of the Kremlin’s grand Victory Day celebrations, as Ukraine accused Russia’s army of launching air strikes just hours into a supposed truce. More than 20 foreign leaders were in Russia to attend a vast military parade today marking 80 years since the defeat of Nazi Germany in World War II, taking place three years into Russia’s offensive in Ukraine. Putin ordered troops into Ukraine in February 2022 and has marshaled the memory of Soviet victory against Nazi Germany to justify his campaign and rally society behind the offensive,
FRAUD ALLEGED: The leader of an opposition alliance made allegations of electoral irregularities and called for a protest in Tirana as European leaders are to meet Albanian Prime Minister Edi Rama’s Socialist Party scored a large victory in parliamentary elections, securing him his fourth term, official results showed late on Tuesday. The Socialist Party won 52.1 percent of the vote on Sunday compared with 34.2 percent for an alliance of opposition parties led by his main rival Sali Berisha, according to results released by the Albanian Central Election Commission. Diaspora votes have yet to be counted, but according to initial results, Rama was also leading there. According to projections, the Socialist Party could have more lawmakers than in 2021 elections. At the time, it won 74 seats in the
RSS